New Advisory for GSK and Pfizer's RSV Vaccines Due to Rare Neurological Disorder Risks

New Advisory for GSK and Pfizer's RSV Vaccines Due to Rare Neurological Disorder Risks
3 months ago

In a newly released advisory, health authorities have notified clinicians and the public about a potential risk associated with the respiratory syncytial virus (RSV) vaccines developed by GSK and Pfizer. These vaccines, which have been hailed as significant advancements in the fight against RSV, are now under scrutiny due to reports revealing a rare neurological disorder potentially linked to their use.

Continue reading
GSK's RSV Vaccine Demonstrates Long-Lasting Protection Across Multiple Seasons

GSK's RSV Vaccine Demonstrates Long-Lasting Protection Across Multiple Seasons
6 months ago

In a significant development for public health, GlaxoSmithKline (GSK) has announced that its respiratory syncytial virus (RSV) vaccine shows promising durability in its protective effects, extending its efficacy over a remarkable three seasons. This finding is pivotal as RSV poses a substantial risk, particularly for infants and elderly populations, leading to severe respiratory illnesses and hospitalizations each year.

Continue reading